Find a Clinical Trial | Tufts Medicine

Filter

Showing 1 - 1 out of 1

OCEANIC-STROKE

A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA

Ischemic stroke, Transient ischemic attack

All genders

18+

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more